CIK 0001622229 · Large accelerated filer
Cogent Biosciences, Inc.
Sign in to watch- Ticker
- COGT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 465308248
- Phone
- 617-945-5576
- Business address
- 180 THIRD AVENUE, 4TH FLOOR, WALTHAM, MA
- Former names
- Unum Therapeutics Inc., Unum Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,689,493
- in 1 filing, $1.7M under 10b5-1 plans
Net −$1,689,493. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-07 | Morris Arlene Director | Grant or award · Stock Option (Right to Buy) | +30,700 | 30,700 | ||
| 2022-06-07 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +30,700 | 30,700 | ||
| 2022-06-07 | CAIN CHRISTOPHER W. Director | Grant or award · Stock Option (Right to Buy) | +30,700 | 30,700 | ||
| 2022-06-07 | Harwin Peter Evan Director | Grant or award · Stock Option (Right to Buy) | +30,700 | 30,700 | ||
| 2022-06-07 | Shegog Todd Director | Grant or award · Stock Option (Right to Buy) | +30,700 | 30,700 | ||
| 2022-04-01 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +2,753 | $4.86 | $13K | 2,753 |
| 2022-04-01 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +2,650 | $4.86 | $13K | 2,650 |
| 2022-01-25 | Green John L. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +225,000 | $4.94 | $1.1M | 225,000 |
| 2022-01-25 | Sachs Jessica Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +250,000 | $4.94 | $1.2M | 250,000 |
| 2022-01-25 | Kearns Evan Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +202,250 | $4.94 | $1000K | 202,250 |
| 2022-01-25 | Robinson John Edward Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +250,000 | $4.94 | $1.2M | 250,000 |
Page 7 of 7 · 131 trades